Moretto, Roberto
Rossini, Daniele
Conca, Veronica http://orcid.org/0000-0001-7713-4005
Lonardi, Sara http://orcid.org/0000-0002-7593-8138
Rasola, Cosimo
Antoniotti, Carlotta
Santini, Daniele
Marmorino, Federica
Tomasello, Gianluca
Borelli, Beatrice
Caponnetto, Salvatore
Zucchelli, Gemma
Zaniboni, Alberto
Ambrosini, Margherita
Buonadonna, Angela
Fanchini, Laura
Cupini, Samanta
Masi, Gianluca
Falcone, Alfredo
Cremolini, Chiara http://orcid.org/0000-0002-0520-4841
Article History
Received: 2 January 2021
Revised: 5 June 2021
Accepted: 30 June 2021
First Online: 12 July 2021
Competing interests
: DR: travel, accommodations and expenses—Takeda. SL: consulting or advisory role—Amgen, Lilly, Merck Serono and Servier. Speakers’ Bureau—Bristol-Myers Squibb, Lilly, Merck Serono, Roche and Servier. Research funding—Amgen and Merck Serono. AZ: consulting or advisory role—Amgen, Bayer, Merck Serono and Servier. Speakers’ Bureau—Servier. AF: honoraria—Amgen, Lilly, Merck, Roche and Servier. Consulting or advisory role—Amgen, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche and Servier. Research funding—Amgen (Inst), Bayer (Inst), Merck (Inst), MSD (Inst), Roche (Inst), Sanofi (Inst) and Servier (Inst). Travel, accommodations and expenses—Amgen, Bayer, Merck, Roche and Servier. CC: honoraria—Amgen, Bayer, Merck, Roche and Servier. Consulting or advisory role—Amgen, Bayer, MSD, Roche. Speakers’ Bureau—Servier. Research funding—Bayer, Merck, Servier. Travel, accommodations and expenses—Roche and Servier. The remaining authors declare no competing interests.
: All patients provided written informed consent to study procedures before enrolment. TRIBE and TRIBE2 studies were conducted in accordance with the Declaration of Helsinki. Approval for TRIBE and TRIBE2 protocols were obtained from local ethics committees of participating sites.
: Not applicable.
Free to read: This content has been made available to all.